- Home
- BEAT vs CRVO Comparison
BEAT vs CRVO Comparison
Compare BEAT & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAT | CRVO |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | 16 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 35.9M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | BEAT | CRVO |
|---|---|---|
| Price | $0.90 | $3.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.63 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 1.4M | 33.5K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $315.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $3.51 |
| 52 Week High | $4.00 | $13.13 |
Technical Indicators
Market Signals| Indicator | BEAT | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 41.46 | 52.05 |
| Support Level | $0.80 | $3.57 |
| Resistance Level | $1.26 | $4.33 |
| Average True Range (ATR) | 0.06 | 0.23 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 60.93 | 62.62 |
Price Performance
Historical ComparisonAbout BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.